Home
/ AstraZeneca
/ Financials & Metrics

AstraZeneca (AZN.L) stock price, revenue, and financials

AstraZeneca market cap is £109.5 b, and annual revenue was $24.38 b in FY 2019

View Company

£109.5 B

AZN.L Mkt cap, 11-Jun-2021

$6.6 B

AstraZeneca Revenue Q3, 2020

AstraZeneca Gross profit (Q3, 2020)5.2 B

AstraZeneca Gross profit margin (Q3, 2020), %79.2%

AstraZeneca Net income (Q3, 2020)651 M

AstraZeneca EBIT (Q3, 2020)1.2 B

AstraZeneca Cash, 30-Sept-20208.1 B

AstraZeneca EV123.7 B

AstraZeneca Revenue

AstraZeneca revenue was $24.38 b in FY, 2019 which is a 10.4% year over year increase from the previous period.

Embed Graph

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Revenue	22.5b	22.1b	24.4b
Revenue growth, %	(2%)	(2%)	10%
Cost of goods sold	4.3b	4.9b	4.9b
Gross profit	18.1b	17.2b	19.5b
Gross profit Margin, %	81%	78%	80%
Sales and marketing expense	310.0m	331.0m	339.0m
R&D expense	5.8b	5.9b	6.1b
General and administrative expense	10.2b	10.0b	11.7b
Operating expense total	16.3b	16.3b	18.1b
EBIT	3.7b	3.4b	2.9b
EBIT margin, %	16%	15%	12%
Interest expense	664.0m	741.0m	772.0m
Interest income	70.0m	96.0m	123.0m
Pre tax profit	2.2b	2.0b	1.5b
Income tax expense	(641.0m)	(57.0m)	321.0m
Net Income	2.9b	2.1b	1.2b
EPS	2.4	1.7	1.0

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Revenue	5.4b	5.1b	6.2b	5.2b	5.2b	5.3b	5.5b	5.8b	6.4b	6.4b	6.3b	6.6b
Cost of goods sold	894.0m	950.0m	1.2b	1.1b	1.0b	1.2b	1.1b	1.1b	1.4b	1.4b	984.0m	1.4b
Gross profit	4.5b	4.1b	5.0b	4.0b	4.1b	4.2b	4.4b	4.8b	5.1b	4.9b	5.3b	5.2b
Gross profit Margin, %	83%	81%	80%	78%	80%	78%	79%	82%	79%	78%	84%	79%
Sales and marketing expense	77.0m	72.0m	76.0m	81.0m	84.0m	73.0m	2.5b	81.0m	88.0m	87.0m	104.0m	99.0m
R&D expense	1.5b	1.3b	1.4b	1.3b	1.4b	1.3b	1.3b	1.4b	1.3b	1.4b	1.4b	1.5b
General and administrative expense	2.3b	2.4b	2.5b	2.5b	2.6b	2.4b	2.5b	2.9b	3.2b	2.7b	2.6b	2.7b
Operating expense total	3.8b	3.8b	4.0b	3.8b	4.0b	3.8b	6.3b	4.4b	4.6b	4.2b	4.1b	4.3b
EBIT	917.0m	925.0m	1.1b	696.0m	763.0m	851.0m	1.1b	493.0m	757.0m	1.2b	1.3b	1.2b
EBIT margin, %	17%	18%	18%	13%	15%	16%	20%	8%	12%	19%	20%	18%
Pre tax profit	582.0m	492.0m	746.0m	374.0m	412.0m	477.0m	758.0m	141.0m	409.0m	935.0m	961.0m	853.0m
Income tax expense	70.0m	46.0m	97.0m	58.0m	93.0m	71.0m	195.0m	34.0m	129.0m	185.0m	223.0m	202.0m
Net Income	512.0m	446.0m	649.0m	316.0m	319.0m	406.0m	563.0m	107.0m	280.0m	750.0m	738.0m	651.0m
EPS	0.4	0.4	0.5	0.3	0.3	0.3	0.5	0.1	0.2	0.6	0.6	0.5

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Cash	3.3b	4.8b	5.4b
Accounts Receivable	2.8b	3.0b	3.6b
Inventories	3.0b	2.9b	3.2b
Current Assets	13.2b	15.6b	15.6b
PP&E	7.6b	7.4b	7.7b
Goodwill	11.8b	11.7b	11.7b
Total Assets	63.4b	60.7b	61.4b
Accounts Payable	3.6b	1.7b	1.8b
Short-term debt	2.2b	1.8b	2.0b
Current Liabilities	16.4b	16.3b	18.1b
Long-term debt	15.6b	17.4b	16.2b
Non-Current Liabilities	30.3b	30.3b	28.7b
Total Debt	17.8b	19.1b	18.2b
Total Liabilities	46.7b	46.6b	46.8b
Common Stock	317.0m	317.0m	328.0m
Additional Paid-in Capital	4.4b	4.4b	7.9b
Retained Earnings	8.2b	5.7b	2.8b
Total Equity	16.6b	14.0b	14.6b
Debt to Equity Ratio	1.1 x	1.4 x	1.2 x
Debt to Assets Ratio	0.3 x	0.3 x	0.3 x
Financial Leverage	3.8 x	4.3 x	4.2 x

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Cash	3.1b	5.2b	4.0b	3.0b	3.0b	3.4b	4.1b	5.4b	4.0b	3.4b	5.7b	8.1b
Inventories	2.7b	2.9b	3.2b	3.3b	3.1b	3.0b	3.1b	3.2b	3.1b	3.1b	3.6b	3.7b
Current Assets	11.6b	14.3b	13.6b	13.2b	12.4b	13.1b	13.6b	15.2b	13.5b	12.8b	14.9b	18.2b
PP&E	7.0b	7.1b	7.3b	7.7b	7.5b	7.6b	7.4b	7.4b	7.3b	7.3b	7.5b	7.7b
Goodwill	11.7b	11.8b	11.8b	11.8b	11.7b	11.7b	11.7b	11.7b	11.6b	11.6b	11.6b	11.7b
Total Assets	61.0b	65.1b	64.6b	63.3b	61.3b	61.4b	61.1b	61.9b	58.9b	57.2b	59.9b	64.1b
Short-term debt	2.8b	2.9b	941.0m	4.2b	4.2b	2.5b	3.7b	1.8b	577.0m	2.5b	4.1b	3.6b
Current Liabilities	15.4b	15.7b	14.5b	18.2b	17.2b	15.2b	18.3b	16.0b	14.8b	17.0b	18.2b	18.9b
Long-term debt	14.6b	16.8b	16.9b	15.7b	15.5b	18.4b	17.9b	17.9b	17.6b	16.1b	15.6b	18.8b
Non-Current Liabilities	30.8b	34.1b	34.7b	30.5b	29.9b	32.7b	30.8b	30.8b	30.5b	28.0b	28.1b	31.6b
Total Debt	17.4b	19.7b	17.9b	19.9b	19.7b	20.9b	21.6b	19.7b	18.2b	18.6b	19.7b	22.3b
Total Liabilities	46.2b	49.7b	49.1b	48.7b	47.1b	47.9b	49.0b	46.8b	45.2b	45.0b	46.3b	50.5b
Common Stock	316.0m	316.0m	316.0m	317.0m	317.0m	317.0m	317.0m	328.0m	328.0m	328.0m	328.0m	328.0m
Additional Paid-in Capital	4.4b	4.4b	4.4b	4.4b	4.4b	4.4b	4.4b	7.9b	7.9b	7.9b	8.0b	8.0b
Retained Earnings	6.3b	6.9b	7.0b	6.2b	5.9b	5.2b	3.7b	3.3b	1.9b	448.0m	1.9b	1.9b
Total Equity	14.8b	15.4b	15.4b	14.6b	14.3b	13.5b	12.0b	15.1b	13.7b	12.2b	12.2b	13.6b
Debt to Equity Ratio	1.2 x	1.3 x	1.2 x	1.4 x	1.4 x	1.5 x	1.8 x	1.3 x	1.3 x	1.5 x	1.6 x	1.6 x
Debt to Assets Ratio	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.4 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x
Financial Leverage	4.1 x	4.2 x	4.2 x	4.3 x	4.3 x	4.5 x	5.1 x	4.1 x	4.3 x	4.7 x	4.9 x	4.7 x

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Net Income	2.9b	2.1b	1.2b
Depreciation and Amortization	3.0b	3.8b	3.8b
Accounts Receivable	83.0m	(523.0m)	(898.0m)
Inventories	(548.0m)	(13.0m)	(316.0m)
Accounts Payable	415.0m	(103.0m)	868.0m
Cash From Operating Activities	3.6b	2.6b	3.0b
Purchases of PP&E	(1.3b)	(1.0b)	(979.0m)
Cash From Investing Activities	(2.3b)	963.0m	(657.0m)
Short-term Borrowings	336.0m	(98.0m)	(516.0m)
Long-term Borrowings	(1.8b)	(1.4b)	(1.7b)
Dividends Paid	(3.5b)	(3.5b)	(3.6b)
Cash From Financing Activities	(2.9b)	(2.0b)	(1.8b)
Net Change in Cash	(1.7b)	1.5b	547.0m
Interest Paid	698.0m	676.0m	774.0m
Income Taxes Paid	454.0m	537.0m	1.1b

Quarterly

USD	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Depreciation and Amortization	658.0m	1.3b	1.9b	709.0m	1.4b	2.1b	676.0m	1.4b	2.1b	841.0m	1.6b	2.4b
Cash From Operating Activities	88.0m	338.0m	2.6b	(140.0m)	(75.0m)	394.0m	(387.0m)	491.0m	1.6b	139.0m	1.2b	3.0b
Purchases of PP&E	(286.0m)	(549.0m)	(849.0m)	(213.0m)	(486.0m)	(728.0m)	(174.0m)	(438.0m)	(659.0m)	(186.0m)	(370.0m)	(598.0m)
Cash From Investing Activities	(146.0m)	(351.0m)	(686.0m)	273.0m	177.0m	36.0m	328.0m	(789.0m)	(715.0m)	9.0m	157.0m	(423.0m)
Short-term Borrowings	352.0m	541.0m	361.0m	1.7b	1.9b	241.0m	1.2b	(64.0m)	(555.0m)	176.0m	1.4b	858.0m
Long-term Borrowings	(14.0m)	(10.0m)	(1.8b)				(42.0m)	(584.0m)	(1.6b)	(53.0m)	(107.0m)	(157.0m)
Dividends Paid	(2.4b)	(2.4b)	(3.5b)	(2.4b)	(2.4b)	(3.5b)	(2.4b)	(2.4b)	(3.6b)	(2.4b)	(2.4b)	(3.6b)
Cash From Financing Activities	(2.0b)	146.0m	(2.9b)	(663.0m)	(481.0m)	(312.0m)	(698.0m)	941.0m	(1.8b)	(2.4b)	(1.2b)	7.0m
Net Change in Cash	(2.1b)	133.0m	(1.0b)	(530.0m)	(379.0m)	118.0m	(757.0m)	643.0m	(892.0m)	(2.2b)	100.0m	2.6b
Interest Paid	189.0m	334.0m	519.0m	128.0m	296.0m	457.0m	208.0m	378.0m	575.0m	180.0m	338.0m	517.0m
Income Taxes Paid	62.0m	336.0m	473.0m	117.0m	288.0m	406.0m	334.0m	723.0m	965.0m	477.0m	792.0m	1.2b

USD	Q1, 2017
Debt/Equity	1.2 x
Debt/Assets	0.3 x
Financial Leverage	4.1 x

	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	Q1, 2018	Q2, 2018	Q3, 2018	Q4, 2018	FY, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q4, 2019	FY, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q4, 2020	FY, 2020
Projects in R&D Pipeline	99	133	146	132	144					149					167					171
Phase I Trials Projects	33	24	44	41	50					38					34					35
Phase II Trials Projects	27	11	33	36	37					43					50					42
Phase III Trials Projects	19	11	35	27	23					22					27					25
Life-cycle Management Projects					34					46					56					69
Blood Pressure Screenings (Africa)					5.7 m					9.97 m					13.5 m					16.7 m
New Phase I Projects						5	3	4	3		1	1	1	5	5	3		3	5	5
New Phase II Projects						2		3	4		12	1	4	5	5	1	4	3	8	8
New Pivotal Study Projects						2	1	5	6		6	6	3	1			5	6	8	8
New Projects to Registration						3	1	3			1		5	5			1	3	2	2
NME Phase I (Oncology)					21	19	18	17	26	26	21	21	20	18	18	20	19	20	21	21
NME Phase II (Oncology)					3	4	10	10	20	20	25	22	25	27	27	25	24	25	21	21
NME in Late-stage Development (Oncology)					5	4	4	4	11	11	14	17	14	12	12	7	9	10	10	10
NME Phase I (Biopharmaceuticals)					13	12	12	13	13	13	13	13	14	16	16	17	16	17	14	14
NME Phase II (Biopharmaceuticals)					18	17	17	17	23	23	22	22	21	22	22	20	21	21	21	21
NME in Late-stage Development (Biopharmaceuticals)					4	4	3	2	3	3	3	3	5	5	5	4	6	5	5	5
Healthcare Workers Trained					10.82 k					35.89 k					81.61 k					132.25 k
People Reached (Healthcare Programmes)					7.17 m					12.01 m					16.42 m					25.03 m
People Reached (Patient Assistance Programmes)					9 m					9.3 m					9.7 m					10.1 m
NME Phase I					34					26					32					27
NME Phase II					20					25					39					36
NME in Late-stage Development					11					8					8					10
Countries					100					100					100					100
Health Facilities Activated					827					2 k					2.62 k					3.36 k
Patients Included in Clinical Trials					33 k
Scientific Collaborations					600					630					730					800
Young Health Programme Members					2.25 m					3.01 m					4.01 m

	FY, 2020
Сorporate Сontributions	20.4 m
Working Days Lost per Year due to Accidents	46.41
Water Used	3.44 m cubic meters
Wastewater Chemical Oxygen Demand	343 metric tons
Waste Recycled	12.15 k metric tons
Waste Generated	30.26 k metric tons
Volunteer Hours	28.44 k
Total Recordable Incident Rate	0.63
Total Greenhouse Gas Emissions	8.05 m metric tons of carbon dioxide equivalent
Solvent Volatile Organic Compound Emissions	199 metric tons of carbon dioxide equivalent
Solvent Volatile Organic Compound Consumptions	3.58 k metric tons of carbon dioxide equivalent
Nonhazardous Waste Generated	19.76 k metric tons
Lost Time Incident Rate (Employees)	0.42
Lost Time Incident Rate (Construction Contractors)	1.48
Hazardous Waste Generated	10.5 k metric tons
Greenhouse Gas Emissions (Scope 3, Waste Generated in Operations)	24.9 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Use of Sold Products)	978.9 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Upstream Transportation and Distribution)	247.96 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Upstream Leased Assets)	46.06 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Purchased Goods and Services)	5.77 m metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Fuel and Energy-Related Activities)	50.36 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, End-of-Life Treatment of Sold Products)	72.07 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Employee Commuting)	35.21 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Downstream Transportation and Distribution)	377.77 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Downstream Leased Assets)	5.95 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Capital Goods)	116.06 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3, Business Travel)	80.8 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 3)	7.8 m metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 2, Market-Based)	23.24 k metric tons of carbon dioxide equivalent
Greenhouse Gas Emissions (Scope 1)	224.77 k metric tons of carbon dioxide equivalent
Energy Used (Renewables)	674.02 k MWh
Energy Used (Power and Heat Renewables)	5.26 k MWh
Energy Used (Imported Renewables)	668.76 k MWh
Energy Used	1.6 m MWh

Gender

	FY, 2019	FY, 2018	FY, 2017
Male, percent	10%	10%	10%
Male (Senior and Middle Management), percent	10.9%	11.1%	11.1%
Female (Senior and Middle Management), percent	9.1%	8.9%	8.9%
Female (Management), percent	8.3%	8.3%	8.1%
Female (Executive Leadership), percent	6.4%	6%	5.6%
Male (Executive Leadership), percent	13.6%	14%	14.4%
Female (Board), percent	6.7%	8.4%	8.4%
Male (Board), percent	13.3%	11.6%	11.6%
Male (Management), percent	11.7%	11.7%	11.9%
Female, percent	10%	10%	10%